Charles Dorego, PhD Charles “Charlie” Dorego is the Senior Vice President and General Counsel of Glenwood Management Corp., one of the largest and most preeminent real estate development companies in New York City. Charlie brings nearly 30 years of diverse, hands-on experience in all aspects of the Real Estate industry. He joined Glenwood Management in […]
Federica del Monte, MD, PhD Federica del Monte is a clinician-scientist, Associate Professor in Medicine in the Department of Medicine, Division of Cardiology at the Medical University of South Carolina, Director of the Christie’s Heart & Brain Program. This will represent the first program to study the mechanisms linking those two diseases either as a systemic
Federica del Monte Read More »
Hui Zheng, PhD Dr. Zheng is a leading authority on amyloid precursor protein (APP) and the presenilins, two proteins involved in the APP processing pathway that produces the Alzheimer’s-linked fragment beta-amyloid. Working with molecular and cellular techniques and genetically engineered mice, she has conducted field-leading explorations of the mechanisms through which rare genetic changes in
George Bartzokis, MD, PhD Dr. George Bartzokis was born in a Greek refugee camp in Romania and at the age of fourteen, he immigrated along with his family to Boston, MA. Once there, he taught himself English, worked his way through school, and eventually graduated from Harvard College. He then went on to earn his
Benjamin Wolozin, MD, PhD Dr. Wolozin’s interests focus on the pathophysiology of Alzheimer’s and Parkinson’s disease. His work on Alzheimer’s disease examines the role of cholesterol in the pathophysiology of Alzheimer’s disease, and stems from his discovery in 2000 that subjects taking the cholesterol lowering medicines, termed statins, have a lower incidence of Alzheimer’s disease.
Karen Duff, PhD Dr. Karen Duff has worked on Alzheimer’s disease for more than 15 years, first creating transgenic mouse models of the disease, then testing therapeutic approaches to treating the disease in the mouse models. Lately, her lab has started looking at other neurodegenerative diseases including Tauopathies and Parkinson’s disease.Dr. Duff’s work on AD
Rebecca Melrose, PhD Linkedin Google My research uses a combination of MRI (task based fMRI, resting state fMRI, DTI) and neuropsychological testing to understand changes to the neural circuitry supporting executive functioning in patients at risk for Alzheimer’s Disease (AD). I am also interested in understanding changes to day to day functioning in aging and
Swati Rane Levendovszky, PhD Linkedin Twitter Google The primary focus of my research is the development of novel perfusion imaging approaches to better understand cerebrovascular pathology. Specifically, I am interested in investigating the relation of hemodynamic factors such as cerebral blood flow (CBF) and cerebral blood volume (CBV) as well as metabolic demands or oxygen
Swati Rane Levendovszky Read More »
Jennifer Yokoyama, PhD Linkedin Twitter Facebook Google Jennifer Yokoyama obtained her doctorate degree in Pharmaceutical Sciences and Pharmacogenomics from UCSF in December 2010 with Dr. Steven Hamilton (Department of Psychiatry and Institute for Human Genetics). Her dissertation comprised work within the Canine Behavioral Genetics Project, utilizing purebred dogs as genetic models for studying neuropsychiatric disease.
Roger Lefort, PhD Linkedin Twitter The main focus of my lab is to elucidate the molecular mechanism(s) leading to synaptic dysfunction and synaptic pruning in various neurodegenerative diseases, such as Alzheimer’s and Huntington disease. Our research has implicated the Rho-family GTPases, RhoA and Rac1, as key players in these synaptopathies. RhoA and Rac1 play critical
